Iconix Signs DrugMatrix Deals with Lilly and FDA s Interdisciplinary Pharmacogenomic Review Group | GenomeWeb

NEW YORK, Nov. 17 (GenomeWeb News) - Iconix Pharmaceuticals has licensed its DrugMatrix chemogenomics system and Drug Signatures library to Elli Lilly and renewed a deal with the US Food and Drug Administration for the DrugMatrix system, the firm said today.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.